Biotechnology
Compare Stocks
5 / 10Stock Comparison
CDT vs BX vs KKR vs APO vs ARES
Revenue, margins, valuation, and 5-year total return — side by side.
Asset Management
Asset Management
Asset Management - Global
Asset Management
CDT vs BX vs KKR vs APO vs ARES — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Asset Management | Asset Management | Asset Management - Global | Asset Management |
| Market Cap | $368K | $95.85B | $89.45B | $73.67B | $40.44B |
| Revenue (TTM) | $696M | $13.83B | $19.26B | $30.30B | $6.47B |
| Net Income (TTM) | $17M | $3.02B | $2.37B | $4.48B | $527M |
| Gross Margin | 36.9% | 86.0% | 41.8% | 88.5% | 74.8% |
| Operating Margin | 6.4% | 51.9% | 2.4% | 34.4% | 27.2% |
| Forward P/E | 0.0x | 20.7x | 16.9x | 14.9x | 20.9x |
| Total Debt | $1.29B | $13.31B | $54.77B | $13.36B | $14.91B |
| Cash & Equiv. | $390M | $2.63B | $6M | $19.24B | $1.50B |
CDT vs BX vs KKR vs APO vs ARES — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 22 | May 26 | Return |
|---|---|---|---|
| CDT Equity Inc. (CDT) | 100 | 0.0 | -100.0% |
| Blackstone Inc. (BX) | 100 | 97.5 | -2.5% |
| KKR & Co. Inc. (KKR) | 100 | 175.3 | +75.3% |
| Apollo Global Manag… (APO) | 100 | 214.9 | +114.9% |
| Ares Management Cor… (ARES) | 100 | 155.4 | +55.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CDT vs BX vs KKR vs APO vs ARES
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CDT has the current edge in this matchup, primarily because of its strength in growth and value.
- 8.9% revenue growth vs KKR's -11.0%
- Lower P/E (0.0x vs 20.9x)
BX is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 21.8% margin vs CDT's 2.4%
- 6.5% ROA vs KKR's 0.6%, ROIC 16.1% vs 0.3%
Among these 5 stocks, KKR doesn't own a clear edge in any measured category.
APO ranks third and is worth considering specifically for sleep-well-at-night and valuation efficiency.
- Lower volatility, beta 1.43, Low D/E 31.4%, current ratio 0.78x
- PEG 0.20 vs ARES's 1.19
- Beta 1.43 vs CDT's 1.84, lower leverage
- +0.4% vs CDT's -99.8%
ARES is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 7 yrs, beta 1.62, yield 6.6%
- Rev growth 66.6%, EPS growth -5.3%
- 9.3% 10Y total return vs APO's 7.6%
- Beta 1.62, yield 6.6%, current ratio 2.24x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.9% revenue growth vs KKR's -11.0% | |
| Value | Lower P/E (0.0x vs 20.9x) | |
| Quality / Margins | 21.8% margin vs CDT's 2.4% | |
| Stability / Safety | Beta 1.43 vs CDT's 1.84, lower leverage | |
| Dividends | 6.6% yield, 7-year raise streak, vs BX's 6.3%, (1 stock pays no dividend) | |
| Momentum (1Y) | +0.4% vs CDT's -99.8% | |
| Efficiency (ROA) | 6.5% ROA vs KKR's 0.6%, ROIC 16.1% vs 0.3% |
CDT vs BX vs KKR vs APO vs ARES — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CDT vs BX vs KKR vs APO vs ARES — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
APO leads in 2 of 6 categories
BX leads 1 • CDT leads 1 • ARES leads 1 • KKR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
BX leads this category, winning 2 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
APO is the larger business by revenue, generating $30.3B annually — 43.5x CDT's $696M. BX is the more profitable business, keeping 21.8% of every revenue dollar as net income compared to CDT's 2.4%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $696M | $13.8B | $19.3B | $30.3B | $6.5B |
| EBITDAEarnings before interest/tax | $47M | $7.2B | $9.0B | $11.5B | $1.8B |
| Net IncomeAfter-tax profit | $17M | $3.0B | $2.4B | $4.5B | $527M |
| Free Cash FlowCash after capex | -$6M | $3.5B | $7.5B | $5.4B | $1.5B |
| Gross MarginGross profit ÷ Revenue | +36.9% | +86.0% | +41.8% | +88.5% | +74.8% |
| Operating MarginEBIT ÷ Revenue | +6.4% | +51.9% | +2.4% | +34.4% | +27.2% |
| Net MarginNet income ÷ Revenue | +2.4% | +21.8% | +12.3% | +14.8% | +8.2% |
| FCF MarginFCF ÷ Revenue | -0.9% | +12.6% | +49.4% | +24.6% | +23.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +100.4% | +41.3% | -1.7% | +16.3% | -80.9% |
Valuation Metrics
CDT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 0.0x trailing earnings, CDT trades at a 100% valuation discount to ARES's 62.8x P/E. Adjusting for growth (PEG ratio), APO offers better value at 0.23x vs ARES's 3.56x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $367,825 | $95.8B | $89.4B | $73.7B | $40.4B |
| Enterprise ValueMkt cap + debt − cash | $896M | $106.5B | $144.2B | $67.8B | $53.9B |
| Trailing P/EPrice ÷ TTM EPS | 0.00x | 31.53x | 42.88x | 17.60x | 62.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 20.74x | 16.89x | 14.94x | 20.92x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.51x | — | 0.23x | 3.56x |
| EV / EBITDAEnterprise value multiple | 2.43x | 14.77x | 20.24x | 5.92x | 26.88x |
| Price / SalesMarket cap ÷ Revenue | 0.00x | 6.93x | 4.64x | 2.43x | 6.25x |
| Price / BookPrice ÷ Book value/share | 0.00x | 4.37x | 1.17x | 1.83x | 3.08x |
| Price / FCFMarket cap ÷ FCF | — | 54.93x | 9.39x | 9.89x | 26.19x |
Profitability & Efficiency
Evenly matched — CDT and APO each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
BX delivers a 14.3% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $3 for CDT. APO carries lower financial leverage with a 0.31x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARES's 1.71x. On the Piotroski fundamental quality scale (0–9), ARES scores 8/9 vs APO's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.6% | +14.3% | +3.2% | +12.1% | +6.2% |
| ROA (TTM)Return on assets | +1.0% | +6.5% | +0.6% | +1.0% | +1.9% |
| ROICReturn on invested capital | +21.9% | +16.1% | +0.3% | +16.0% | +6.1% |
| ROCEReturn on capital employed | +22.2% | +16.9% | +0.1% | +8.8% | +7.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 6 | 3 | 8 |
| Debt / EquityFinancial leverage | 1.02x | 0.61x | 0.67x | 0.31x | 1.71x |
| Net DebtTotal debt minus cash | $896M | $10.7B | $54.8B | -$5.9B | $13.4B |
| Cash & Equiv.Liquid assets | $390M | $2.6B | $6M | $19.2B | $1.5B |
| Total DebtShort + long-term debt | $1.3B | $13.3B | $54.8B | $13.4B | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | -1.05x | 14.12x | 3.29x | 28.98x | 2.68x |
Total Returns (Dividends Reinvested)
APO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARES five years ago would be worth $26,021 today (with dividends reinvested), compared to $0 for CDT. Over the past 12 months, APO leads with a +0.4% total return vs CDT's -99.8%. The 3-year compound annual growth rate (CAGR) favors APO at 29.2% vs CDT's -97.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -94.2% | -21.3% | -22.0% | -12.5% | -25.1% |
| 1-Year ReturnPast 12 months | -99.8% | -6.5% | -13.0% | +0.4% | -21.1% |
| 3-Year ReturnCumulative with dividends | -100.0% | +65.9% | +107.7% | +115.8% | +64.7% |
| 5-Year ReturnCumulative with dividends | -100.0% | +59.0% | +76.5% | +135.1% | +160.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | +476.1% | +715.5% | +759.2% | +929.6% |
| CAGR (3Y)Annualised 3-year return | -97.4% | +18.4% | +27.6% | +29.2% | +18.1% |
Risk & Volatility
APO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
APO is the less volatile stock with a 1.43 beta — it tends to amplify market swings less than CDT's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. APO currently trades 81.3% from its 52-week high vs CDT's 0.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.98x | 1.51x | 1.66x | 1.44x | 1.62x |
| 52-Week HighHighest price in past year | $1425.00 | $190.09 | $153.87 | $157.28 | $195.26 |
| 52-Week LowLowest price in past year | $1.20 | $101.73 | $82.67 | $99.56 | $95.80 |
| % of 52W HighCurrent price vs 52-week peak | +0.1% | +64.3% | +65.2% | +81.3% | +63.1% |
| RSI (14)Momentum oscillator 0–100 | 27.2 | 54.8 | 52.4 | 64.9 | 63.2 |
| Avg Volume (50D)Average daily shares traded | 126K | 7.1M | 6.5M | 5.2M | 3.7M |
Analyst Outlook
ARES leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: BX as "Buy", KKR as "Buy", APO as "Buy", ARES as "Buy". Consensus price targets imply 40.7% upside for KKR (target: $141) vs 23.1% for APO (target: $157). For income investors, ARES offers the higher dividend yield at 6.56% vs KKR's 0.80%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $156.29 | $141.14 | $157.25 | $171.13 |
| # AnalystsCovering analysts | — | 29 | 27 | 28 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | +6.3% | +0.8% | +1.7% | +6.6% |
| Dividend StreakConsecutive years of raises | 1 | 2 | 6 | 3 | 7 |
| Dividend / ShareAnnual DPS | — | $7.70 | $0.80 | $2.14 | $8.08 |
| Buyback YieldShare repurchases ÷ mkt cap | +28.8% | +0.3% | +0.1% | +1.0% | 0.0% |
APO leads in 2 of 6 categories (Total Returns, Risk & Volatility). BX leads in 1 (Income & Cash Flow). 1 tied.
CDT vs BX vs KKR vs APO vs ARES: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CDT or BX or KKR or APO or ARES a better buy right now?
For growth investors, Ares Management Corporation (ARES) is the stronger pick with 66.
6% revenue growth year-over-year, versus -11. 0% for KKR & Co. Inc. (KKR). CDT Equity Inc. (CDT) offers the better valuation at 0. 0x trailing P/E, making it the more compelling value choice. Analysts rate Blackstone Inc. (BX) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CDT or BX or KKR or APO or ARES?
On trailing P/E, CDT Equity Inc.
(CDT) is the cheapest at 0. 0x versus Ares Management Corporation at 62. 8x. On forward P/E, Apollo Global Management, Inc. is actually cheaper at 14. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Apollo Global Management, Inc. wins at 0. 20x versus Ares Management Corporation's 1. 19x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — CDT or BX or KKR or APO or ARES?
Over the past 5 years, Ares Management Corporation (ARES) delivered a total return of +160.
2%, compared to -100. 0% for CDT Equity Inc. (CDT). Over 10 years, the gap is even starker: ARES returned +951. 4% versus CDT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CDT or BX or KKR or APO or ARES?
By beta (market sensitivity over 5 years), Apollo Global Management, Inc.
(APO) is the lower-risk stock at 1. 44β versus CDT Equity Inc. 's 1. 98β — meaning CDT is approximately 37% more volatile than APO relative to the S&P 500. On balance sheet safety, Apollo Global Management, Inc. (APO) carries a lower debt/equity ratio of 31% versus 171% for Ares Management Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — CDT or BX or KKR or APO or ARES?
By revenue growth (latest reported year), Ares Management Corporation (ARES) is pulling ahead at 66.
6% versus -11. 0% for KKR & Co. Inc. (KKR). On earnings-per-share growth, the picture is similar: CDT Equity Inc. grew EPS 128. 8% year-over-year, compared to -28. 7% for KKR & Co. Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CDT or BX or KKR or APO or ARES?
Blackstone Inc.
(BX) is the more profitable company, earning 21. 8% net margin versus 8. 2% for Ares Management Corporation — meaning it keeps 21. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BX leads at 51. 9% versus 2. 4% for KKR. At the gross margin level — before operating expenses — APO leads at 88. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CDT or BX or KKR or APO or ARES more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Apollo Global Management, Inc. (APO) is the more undervalued stock at a PEG of 0. 20x versus Ares Management Corporation's 1. 19x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Apollo Global Management, Inc. (APO) trades at 14. 9x forward P/E versus 20. 9x for Ares Management Corporation — 6. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KKR: 40. 7% to $141. 14.
08Which pays a better dividend — CDT or BX or KKR or APO or ARES?
In this comparison, ARES (6.
6% yield), BX (6. 3% yield), APO (1. 7% yield), KKR (0. 8% yield) pay a dividend. CDT does not pay a meaningful dividend and should not be held primarily for income.
09Is CDT or BX or KKR or APO or ARES better for a retirement portfolio?
For long-horizon retirement investors, Apollo Global Management, Inc.
(APO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1. 7% yield, +790. 9% 10Y return). CDT Equity Inc. (CDT) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (APO: +790. 9%, CDT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CDT and BX and KKR and APO and ARES?
These companies operate in different sectors (CDT (Healthcare) and BX (Financial Services) and KKR (Financial Services) and APO (Financial Services) and ARES (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CDT is a small-cap deep-value stock; BX is a mid-cap high-growth stock; KKR is a mid-cap quality compounder stock; APO is a mid-cap high-growth stock; ARES is a mid-cap high-growth stock. BX, KKR, APO, ARES pay a dividend while CDT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.